O B J E C T I V E S We report optical coherence tomography (OCT) findings in 33 patients who presented with very late stent thrombosis (VLST) after either drug-eluting stent (DES) or bare-metal stent (BMS) implantation.
V ery late stent thrombosis (VLST) is a catastrophic complication that occurs beyond 1 year from stent implantation with a steady frequency of 0.6% per year thereafter in drug-eluting stents (DES) (1) . However, the precise mechanisms of VLST are the subject of debate. Previous pathologic studies report that delayed arterial healing characterized by persistent fibrin deposition and poor endothelialization is the primary substrate of late DES thrombosis (2, 3) . Studies by Cook et al. (4, 5) and a meta-analysis by Hassan et al. (6) suggest that late stent malapposition with expansive vascular remodeling is more frequent after DES implantation than that with bare-metal stent (BMS) implantation and is associated with VLST. An in vivo study by Guagliumi et al. (7) shows that optical coherence tomography (OCT) detected uncovered stent struts are independently associated with late DES thrombosis. Finally, de novo in-stent neoatherosclerosis induced by chronic inflammation and abnormal vascular responses has been suggested as an additional mechanism of VLST (8) (9) (10) . We previously reported grayscale intravascular ultrasonography (IVUS) findings of VLST suggesting that stent malapposition was unique to DES-related VLST, while in-stent neointimal rupture was found in both BMS and DES with VLST (8) . However, grayscale IVUS is limited both in its ability to characterize the neointima and to accurately identify uncovered stent struts, stent coverage, or stent-vessel wall malapposition. Thus, we report high-resolution OCT findings in 33 patients who presented with VLST.
M E T H O D S
Subjects. From February 2009 to September 2011, a total of 55 consecutive patients (36 DES and 19 BMS lesions) presented with definite VLST (beyond 1 year after stent placement) at the Asan Medical Center, Seoul, Korea. Angiographic evidence of definite stent thrombosis was based on Academic Research Consortium criteria (11) . Furthermore, we included only those patients presenting with acute myocardial infarction or patients presenting with unstable angina who had stent thrombosis documented by thrombectomy. Exclusion criteria were hemodynamic instability, balloon pre-dilation, or thrombectomy prior to OCT examination; inability of the OCT ImageWire or DragonFly catheter (LightLab Imaging, Inc., Westford, Massachusetts) to cross the lesion into the distal vessel due to tight stenosis or severe tortuousity; or presence of left main lesions or saphenous vein graft lesions. In addition, before April 2011, OCT examination using the proximal occlusive technique could not be carried out in lesions located near the ostium. Thus, OCT imaging was performed with 36 patients. After excluding 3 patients whose image quality was poor, we included 33 patients with 33 VLST lesions (27 DES and 6 BMS) in the current study. The DES-VLST group included 22 lesions with the Cypher stent (Cypher Select, Cordis, Johnson & Johnson, Miami, Florida), 3 with Taxus stents (Boston Scientific Corp., Natick, Massachusetts), 1 with Xience stent (Abbot Vascular, Santa Clara, California), and 1 with Pico Elite stent (amg International GmbH, Raesfeld-Erle, Germany). Baseline C-reactive protein was measured before the procedure. All patients signed written informed consent prior to the study. Angiographic analysis. Qualitative and quantitative angiographic measurements were taken using standard techniques with automated edge detection algorithms (CAAS-5, Pie-Medical, Maastricht, the Netherlands) in the angiographic analysis center of the CardioVascular Research Foundation, Seoul, Korea (12) . OCT imaging and analysis. All OCT images were acquired before thrombus aspiration or IVUS imaging. Before April 2011, OCT images were acquired using the proximal occlusive technique, the 0.019-inch ImageWire, and a commercially available system (LightLab Imaging, Inc.). The artery was cleared of blood by continuous flushing with iodixanol 370 (Visipaque, GE Health Care, Cork, Ireland) at a flow rate of 3.0 ml/s (13) . Since April 2011, OCT images have been acquired using a nonocclusive technique with the C7XR system (LightLab Imaging, Inc.).
Strut-level OCT analysis was performed every 3 frames (every 0.45 mm in images obtained at 3 mm/s pullback using the occlusive technique or every 0.55 mm in images obtained at 20 mm/s pullback using the nonocclusive technique).
Struts were classified as uncovered when a tissue layer on the endoluminal surface was not visible. Struts were classified as malapposed if the distance from the endoluminal surface of the strut to the adjacent lumen contour was greater than the sum of the metal and polymer thickness, not related to a side branch. Thus, the cutoff points of malapposition used for each stent type were 130 mm for the Taxus paclitaxel-eluting stent; 160 mm for the OCT and Very Late Stent Thrombosis J U N E 2 0 1 3 : 6 9 5 -7 0 3
Cypher sirolimus-eluting stent; and 90 mm for the Xience everolimus-eluting stent (14) . To evaluate the distribution of the uncovered (or malapposed) struts, we calculated the proportion of frames with at least one uncovered (or malapposed) strut for each stented segment.
Neointima was the tissue between the luminal border and the inner border of the struts. Calcific intima had a well-delineated, signal-poor region with sharp borders (15) . A microvessel (evidence of neovascularization) was defined as a small vesicular or tubular structure with a diameter of #200 mm (16) . Thin-cap fibroatheroma (TCFA)-containing intima had a fibrous cap thickness of #65 mm at the thinnest part, and an angle of $180 of lipidic tissue was defined as a signal-poor region with diffuse borders (17) (18) (19) . OCT neointimal rupture was a break in the fibrous cap of the neointima so that the lumen was connected with the underlying ruptured cavity; this definition is analogous to that of plaque rupture seen in native atherosclerotic plaques, as has been reported previously (19, 20) .
Thrombi were masses of $250 mm in diameter protruding into the lumen and discontinuous from the surface of the vessel wall. Red thrombi had high backscattering with signal-free shadowing; and white thrombi were signal-rich and had low backscattering (21, 22) . Thrombus-associated neointimal rupture was located within 5 mm from the thrombus. Similarly, thrombus-associated malapposition was located within 5 mm from the thrombus.
When attenuation caused by large amounts of red thrombus obscured underlying neointima morphology; OCT-detectable TCFA-containing neointima, neointima rupture, or malapposition were identified proximal or distal (or opposite) to the red thrombus. All reported OCT parameters required the agreement of two observers (S.-J.K. and G.S.M.). Examples are shown in Figure 1 . IVUS imaging and analysis. IVUS imaging was performed after OCT image acquisition and after intracoronary administration of 0.2 mg of nitroglycerin, using a motorized transducer pullback (0.5 mm/s) and a commercial scanner (Boston Scientific/SCIMED, Minneapolis, Minnesota) consisting of a rotating 40-MHz transducer within a 3.2-F imaging sheath. Using computerized planimetry (EchoPlaque version 3.0 software, Indec Systems, MountainView, California), stent and reference segments were assessed. Measurements included external elastic membrane (EEM) area, stent area, and minimal lumen area (MLA). Neointimal rupture and stent malapposition were defined as described above (8, 19, 20 
R E S U L T S
Baseline clinical and procedural characteristics. The clinical and procedural characteristics of the 33 patients with definite VLST are summarized in Table 1 . The clinical presentation was ST-segment elevation myocardial infarction (STEMI) in 17 (52%), non-ST-segment elevation myocardial infarction (NSTEMI) in 11 (33%), and unstable angina (with documented thrombus) in 5 (15%). The median follow-up time was 74.1 months (IQR: 45.9 to 90.4 months), overall 61.5 months (IQR: 38.7 to 80.3 months) in 27 DES-treated lesions and 109.1 months (IQR: 93.7 to 135.6 months) in 6 BMS-treated lesions. DES-VLST was related to recent withdrawal of dual antiplatelet therapy in 1 patient. Angiographic and IVUS data are shown in Table 2 . Thrombi, TCFA, and neointimal rupture. OCT findings are summarized in Table 3 . Overall, 31 (94%) lesions showed intraluminal thrombi (93% in DES lesions vs. 100% in BMS lesions, p ¼ 0.665). Combining DES and BMS values, red thrombi were observed in 26 (79%) and white thrombi were seen in 31 (94%) VLST lesions. In the 2 lesions without OCT-detected thrombi, initial angiography showed haziness, and in both lesions, OCT showed abundant neointima and intimal rupture at the MLA site without abnormal OCT findings of the reference segments.
In the overall cohort, combining DES and BMS, neointimal rupture was seen in 23 (70%): 17 lesions with single ruptures and 6 lesions with multiple ruptures; TCFA-containing neointima was seen in 21 (64%). The relationship between the site of the TCFA-containing neointima or site of neointimal rupture and the MLA site was shown in Table 3 .
Stent strut coverage and malapposition. Table 3 summarizes stent strut tissue coverage and malapposition assessed by OCT. In the DES-treated lesions 15 (56%) had at least 1 frame with uncovered struts, and 14 (52%) had at least 1 frame with malapposed struts. Conversely, in the BMS group, all but one lesion showed completely covered stent struts. Mechanisms of VLST. In the overall cohort combining DES and BMS, VLST was associated with in-stent neointimal rupture in 23 (70%) lesions (Fig. 2A) ; all but one had thrombi near the site of the ruptured neointima. Stent malapposition was observed in 14 (42%) lesions, but only 9 (64%) of them showed thrombi within the malapposed segments; moreover, 6 (18%) lesions with malapposition also had neointimal rupture within the stented segment. Only 2 (6%) lesions had no evidence of neointimal rupture or malapposition.
In 27 DES with VLST, neointimal rupture was seen in 17 (63%) and malapposition was seen in 14 (52%); both neointimal rupture and malapposition were seen in 6 (22%). All of the 6 BMS with VLST lesions showed in-stent neointimal rupture without malapposition.
Stent fracture was detected in 3 Cypher-treated lesions. All of the lesions showed abundant neointima containing a TCFA and intimal rupture near the stent fracture. Although expansive remodeling was seen in all of these lesions, only 1 was associated with malapposition of a minimal degree. Clinical correlations. Compared with lesions without neointimal rupture, lesions with neointimal 
arrowhead). (B)
A 51-year-old male presented with STEMI 75 months after Cypher stent placement. A lack of neointimal tissue, and malapposed struts (arrows), and red thrombi (asterisk) were found at the same frame. (C) A very large area of malapposition (arrows) with expansive remodeling and mural thrombus (arrowhead) was found in a 69-year-old male with non-ST-segment elevation myocardial infarction (NSTEMI) 53 months after Cypher stent implantation. Small white thrombi (asterisk) were associated with malapposed stent struts. (D) A 79-year-old male presented with NSTEMI 60 months after Cypher stent implantation. There were intimal ruptures (arrowhead) and underlying thin-cap fibroatheroma (TCFA)-containing neointima (arrows). There were no malapposed struts.
rupture showed a higher frequency of STEMI (65% vs. 20%, respectively, p ¼ 0.040) as well as a higher peak creatine kinase-myocardial band (CK-MB) (163.1 ng/ml [IQR: 21.2 to 302.3 ng/ml] vs. 15.7 ng/ml [IQR: 4.4 to 66.4 ng/ml], respectively, p ¼ 0.017). Furthermore, a TIMI flow grade of 3 was less frequent in lesions with neointimal rupture than in those without neointimal rupture (22% vs. 63%, respectively, p ¼ 0.044). All 3 patients with Cypher stent fracture and VLST presented with STEMI. Figure 2B compares the major OCT findings between 17 patients who presented with STEMI and 16 patients who presented with NSTEMI or unstable angina (with documented thrombus).
D I S C U S S I O N
In-stent neoatherosclerosis has been reported as a mechanism of both DES and BMS failure although it occurs earlier in DES-treated lesions than in BMS-treated lesions (9) . Unstable characteristics such as in-stent TCFA and neointimal rupture have been associated with late thrombotic events both in vitro and in vivo (9, 16, 18, (23) (24) (25) . The major findings of the current report are: 1) all BMS with VLST showed in-stent neointimal rupture without malapposition, consistent with previous data (8, 23, 24) . 2) In DES with VLST, the frequency of neointimal rupture was 63%; and the frequency of malapposition was 52%. However, both malapposition and neointimal rupture were seen in 22%; and thrombi were more often associated with neointimal rupture than with malapposition. 3) Compared with lesions without neointimal rupture, patients with neointimal rupture showed a higher frequency of STEMI with slow flow and a higher peak CK-MB at the time of presentation of VLST.
Unlike BMS-treated lesions with VLST, VLST after DES implantation is multifactorial in causality and varies among the many publications. Cook et al. (4) demonstrated incomplete stent apposition in 77% of patients with VLST, especially a larger malapposition area. In another analysis of thrombus aspirates from patients who presented with VLST, findings suggested that hypersensitivity was a cause and was associated with vascular remodeling and secondary stent malapposition (5) . Using OCT to study 18 patients with DES-VLST, Hong et al. (26) reported that 22% had intimal rupture, while malapposed struts were found in 50%. More recently, Guagliumi et al. (7) evaluated 18 patients with late or very late DES thrombosis and showed higher frequencies of uncovered (12.2% vs. 4.1%, respectively) and malapposed struts (4.6% vs. 1.8%, respectively), while neointimal rupture was seen in only 17%. This study is different from previous OCT studies. In the current study we saw neointimal rupture in 63% of DES-VLST lesions. Although 22% showed both neointimal rupture and malapposition, neointimal rupture more likely contributed to the thrombotic event because of the spatial relationship of the intracoronary thrombus to the site of neointimal rupture. There are 2 plausible explanations for the discrepancy between the frequency of neointimal rupture in the current analysis and that in previous reports (7, 26) . The time between DES implantation and VLST is shorter in previous studies (Hong et al. [26] , 40 AE 18 months; Guagliumi et al. [7] , median 20.5 months) than in our current study (median 61.5 months). The frequency of in-stent neoatherosclerosis, that is, the precursor for neointimal rupture and VLST, is time dependent and is not a consistent finding until approximately 1.5 to 2.0 years post-DES implantation (9, 19) . Moreover, in both previous OCT studies, OCT examination had been done after thrombus aspiration, while in the current analysis, OCT had been performed before thrombus aspiration. A recent study by Kimura et al. (27) shows that aspirates from VLST lesions frequently contain fragments of atherosclerotic intima and thin fibrous cap (27) . Thus, the simple protocol decision whether to perform thrombectomy first or OCT first would affect the diagnosis of the cause of VLST and the published findings. Furthermore, because red thrombus may obscure the presence of neointimal rupture or malapposition, the finding of a "vulnerable" neointima might be underestimated (but not overestimated!), unless thrombectomy is performed first. Thus, our study suggests that advanced neoatherosclerosis with neointimal rupture is the primary mechanism of VLST.
Regarding the remaining 37% of VLST lesions without neointimal rupture, despite a high frequency of malapposed struts, it is uncertain whether malapposition is a direct cause of VLST or merely a marker of an underlying pathobiological process as suggested by Cook (4, 5) . Stent fracture has been associated with peri-stent staining or aneurysmal changes and may be related to late stent thrombosis as well as late catch-up (27) (28) (29) . However, in all 3 DES VLST lesions with stent fracture in our current study, neointimal rupture within abundant neointima has been documented irrespective of presence of malapposition. This suggests an interrelationship among neoatherosclerosis, restenosis, VLST, and stent fracture in some patients.
Compared with patients with VLST without neointimal rupture, patients with VLST and neointimal rupture more often presented with STEMI and had a higher peak CK-MB. Thus, the underlying mechanism of VLST was as important as the VLST event itself; neointimal rupture was associated with more intense clinical sequelae in the setting of stent thrombosis.
We previously reported the following OCT findings of DES restenosis: TCFA-containing neointima in 52%, neointimal rupture in 58% and intraluminal thrombi in 58%, all evidence of "vulnerable" neointima (19) . Unstable clinical presentation was associated with a thinner fibrous cap and a higher frequency of these vulnerable neointima findings. In this report we extend our OCT observations to definite VLST. Study limitations. This was a cross-sectional observational study identifying the mechanisms of VLST, but not the predictive power of OCT in Values are n (%) or n (range). Continuous variables are presented as median values (interquartile ranges) and were compared using a nonparametric Mann-Whitney test. MSA ¼ minimal stent area; OCT ¼ optical coherence tomography; TCFA ¼ thin-cap fibroatheroma; other abbreviations as in Table 1 .
an asymptomatic population. This study had no control group, and there were no serial OCT or follow-up data. Despite the largest patient cohort with definite VLST reported so far, the sample size was still underpowered to perform any subgroup assessment or multivariable analysis. Because of signal attenuation caused by thrombi, accurate assessment of structures behind massive thrombi was limited. Although underlying plaque morphology potentially affected the mechanisms of VLST, OCT artifacts behind stent struts and shallow penetration limited the assessment of peristent plaque. Finally, OCT images included only in-stent and adjacent reference segments and not far proximal or distal segments.
C O N C L U S I O N S
Intracoronary OCT at the time of acute clinical presentation showed that all BMS lesions with VLST and 63% of DES lesions with VLST had in-stent neointimal rupture; and two-thirds of them presented with STEMI, suggesting that advanced neoatherosclerosis was a common and aggressive mechanism of VLST. 
